Bone Biologics Corp

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Balance Sheets

Condensed Consolidated Balance Sheets

	September 30, 2025	December 31, 2024
(unaudited)
Assets
Current Assets
Cash	$6,049,084	$3,325,131
Advances on research and development contract services	220,286	258,059
Prepaid insurance	71,429	268,179
Prepaid expenses	10,000	10,000
Total current assets	$6,350,799	$3,861,369
Total assets	$6,350,799	$3,861,369
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable and accrued expenses	$333,081	$373,042
Warrant liability	1,201	4,670
Total current liabilities	334,282	377,712
Total liabilities	334,282	377,712
Commitments and Contingencies	-	-
Stockholders’ Equity
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at September 30, 2025 and December 31, 2024	-	-
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 1,795,260 and 492,417 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively(1)	1,795	492
Additional paid-in capital(1)	93,460,448	88,504,543
Accumulated deficit	(87,445,726)	(85,021,378)
Total stockholders’ equity	6,016,517	3,483,657
Total liabilities and stockholders’ equity	$6,350,799	$3,861,369

(1)	Adjusted to reflect the reverse stock split as described in Note 1.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.